Business Context and Reporting Period
This Form 8-K Current Report was filed by cbdMD, Inc. on November 28, 2025. The filing discloses the execution of a new Executive Employment Agreement with T. Ronan Kennedy (CEO and CFO) and the Board's approval of a new 2025 Equity Compensation Plan to replace expired prior plans.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and equity plan administration.
- CEO/CFO Base Salary: $340,000 annually.
- Restricted Stock Award: 445,000 shares granted to T. Ronan Kennedy.
- Equity Plan Reserve: 891,316 shares reserved for the 2025 Equity Compensation Plan.
Material Changes
The primary material changes reported are:
- Executive Compensation: A new three-year employment agreement was entered into with the CEO/CFO, effective November 28, 2025.
- Equity Plan Replacement: The 2015 Equity Compensation Plan has expired, and the 2021 Plan has nominal shares remaining. The Board approved the 2025 Plan to facilitate future stock-based awards.
- Shareholder Approval Requirement: Vesting and issuance of the CEO's restricted stock award and the granting of Incentive Stock Options (ISOs) under the new plan are contingent upon shareholder approval at the 2026 annual meeting.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company intends to recommend the 2025 Plan for shareholder approval at the upcoming 2026 annual meeting. The plan includes an "evergreen formula" to automatically increase available shares annually by 2% of outstanding shares (up to 300,000 shares or 10% of total outstanding shares, whichever is less).
Risks and Contingencies:
- Approval Risk: If shareholder approval is not obtained by November 28, 2025, ISOs cannot be awarded, and any previously awarded ISOs will convert to Non-Qualified Stock Options (NQOs).
- Vesting Contingency: Grants under the 2025 Plan will not vest until shareholder approval is received.
- Plan Termination: The 2025 Plan will terminate 10 years from adoption unless suspended or terminated earlier by the Board.
Investor Verification Checklist
- Verify the outcome of the shareholder vote on the 2025 Equity Compensation Plan at the 2026 annual meeting.
- Confirm the vesting schedule and specific performance conditions attached to the 445,000 restricted stock shares granted to the CEO/CFO.
- Monitor the "evergreen" share increase mechanism to assess potential future dilution.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for termination clauses and severance provisions not detailed in this summary.